ATE280769T1 - Verfahren zur herstellung von vitronectin- rezeptorantagonisten - Google Patents

Verfahren zur herstellung von vitronectin- rezeptorantagonisten

Info

Publication number
ATE280769T1
ATE280769T1 AT01974220T AT01974220T ATE280769T1 AT E280769 T1 ATE280769 T1 AT E280769T1 AT 01974220 T AT01974220 T AT 01974220T AT 01974220 T AT01974220 T AT 01974220T AT E280769 T1 ATE280769 T1 AT E280769T1
Authority
AT
Austria
Prior art keywords
producing
receptor antagonists
vitronectin receptor
vitronectin
antagonists
Prior art date
Application number
AT01974220T
Other languages
English (en)
Inventor
Anuschirwan Peyman
Gerrit Schubert
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE280769T1 publication Critical patent/ATE280769T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01974220T 2000-08-31 2001-08-29 Verfahren zur herstellung von vitronectin- rezeptorantagonisten ATE280769T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10042655A DE10042655A1 (de) 2000-08-31 2000-08-31 Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
PCT/EP2001/009985 WO2002018384A1 (en) 2000-08-31 2001-08-29 Process for the preparation of vitronectin receptor antagonists

Publications (1)

Publication Number Publication Date
ATE280769T1 true ATE280769T1 (de) 2004-11-15

Family

ID=7654338

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01974220T ATE280769T1 (de) 2000-08-31 2001-08-29 Verfahren zur herstellung von vitronectin- rezeptorantagonisten

Country Status (8)

Country Link
US (1) US6992187B2 (de)
EP (1) EP1315728B1 (de)
JP (1) JP5047445B2 (de)
AT (1) ATE280769T1 (de)
AU (1) AU2001293791A1 (de)
DE (2) DE10042655A1 (de)
ES (1) ES2232665T3 (de)
WO (1) WO2002018384A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1065207A1 (de) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridin derivate, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende pharmazeutische Zusammenfassungen
FR2847254B1 (fr) * 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
US8472792B2 (en) 2003-12-08 2013-06-25 Divx, Llc Multimedia distribution system
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
PT1984344E (pt) * 2005-12-29 2012-12-21 Lexicon Pharmaceuticals Inc Derivados de aminoácidos multicíclicos e métodos para a sua utilização
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU684036A1 (ru) * 1976-11-01 1979-09-05 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвийской Сср Способ получени производных аденина или их оптических изомеров
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
JPH1180131A (ja) * 1997-09-01 1999-03-26 Mitsubishi Chem Corp エチニルピリミジン誘導体
JP3957023B2 (ja) * 1997-11-12 2007-08-08 三菱化学株式会社 プリン誘導体及びそれを有効成分として含む医薬
EP1065207A1 (de) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridin derivate, Verfahren zu ihrer Herstellung, ihre Anwendung und sie enthaltende pharmazeutische Zusammenfassungen
EP1065208A1 (de) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituierte Purin Derivate als Inhibitoren der Zell-Adhäsion

Also Published As

Publication number Publication date
DE60106778D1 (de) 2004-12-02
JP2004507544A (ja) 2004-03-11
ES2232665T3 (es) 2005-06-01
EP1315728B1 (de) 2004-10-27
DE10042655A1 (de) 2002-03-14
JP5047445B2 (ja) 2012-10-10
US6992187B2 (en) 2006-01-31
DE60106778T2 (de) 2005-12-15
WO2002018384A1 (en) 2002-03-07
EP1315728A1 (de) 2003-06-04
US20040248907A1 (en) 2004-12-09
AU2001293791A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
DE502004009142D1 (de) Verfahren zur herstellung substituierter 3-aryl-butyl-aminverbindungen
DE60214743D1 (de) Verfahren zur herstellung von fischer-tropsch-wachsen
DE60203569D1 (de) Verfahren zur Herstellung von Methanol
EA200600485A1 (ru) Способ получения производных 2-оксо-1-пирролидина
ATE250601T1 (de) Prozess zur herstellung der kristallinen form i von cabergolin
ATE280769T1 (de) Verfahren zur herstellung von vitronectin- rezeptorantagonisten
ATE275149T1 (de) Verfahren zur herstellung von taxanderivaten
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
DE602004003037D1 (de) Verfahren und zwischenprodukte für die herstellung von emtricitabin
DE60142201D1 (de) Verfahren zur Herstellung von einkristallinem Siliziumkarbid
ATE310735T1 (de) Verfahren zur herstellung von spirocyclischen tetronsäurederivaten
ATE352549T1 (de) Verfahren zur herstellung von desloratadin
DE602004004677D1 (de) Verfahren zur herstellung substituierter 5-amino-pyrazolo-ä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine
ATE272038T1 (de) Verfahren zur herstellung von 2-alkyl-3- chlorphenolen
DE60234279D1 (de) Verfahren zur herstellung eines immunosuppresivums
DE60104704D1 (de) Verfahren zur herstellung einer substituierten imidazopyridinverbindung
ATE380183T1 (de) Verfahren zur herstellung von phenyltetrazolderivaten
ATE370950T1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
ATE330612T1 (de) Verfahren zur herstellung von benazeprilhydrochloride
ATE425143T1 (de) Verfahren zur herstellung von indolen
ATE297478T1 (de) Verfahren zur herstellung von orthocarbonsäuretrialkylestern
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
ATE466847T1 (de) Verfahren zur herstellung von 14-beta- hydroxybaccatin-iii-1,14-carbonat
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
ATE404540T1 (de) Verfahren zur herstellung von 1-substituierten 5- chlor-4methylpyrazolen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties